Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR)

Historical Holders from Q3 2020 to Q3 2025

Symbol
KYMR on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
80,797,753
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
80,867,584
Holdings value
$4,576,968,145
% of all portfolios
0.003%
Number of holders
206
Number of buys
116
Number of sells
-92
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 10.9% +14% $551,236,913 +$127,711,627 8,676,797 +30.2% Baker Bros. Advisors LP 09 Dec 2025
BIOTECHNOLOGY VALUE FUND L P 8.5% $436,311,906 6,867,809 BVF PARTNERS L P/IL 11 Dec 2025
FMR LLC 8.2% +20% $332,785,989 +$83,223,338 5,879,611 +33.3% FMR LLC 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 7.7% -16.7% $240,614,612 -$27,985,329 5,372,061 -10.4% Wellington Management Group LLP 30 Jun 2025
VANGUARD GROUP INC 8.05% $173,996,098 5,231,392 The Vanguard Group 31 Mar 2025
PRICE T ROWE ASSOCIATES INC /MD/ 7.1% $288,530,046 5,097,704 T. Rowe Price Associates, Inc. 30 Sep 2025
BlackRock, Inc. 5.4% $165,983,856 3,803,227 BlackRock, Inc. 30 Jun 2025

Institutional Holders of Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 80,867,584 $4,576,968,145 +$137,544,867 $56.6 206
2025 Q2 78,801,021 $3,438,754,240 +$270,821,262 $43.64 208
2025 Q1 72,808,716 $1,995,263,098 +$5,348,226 $27.37 171
2024 Q4 71,721,890 $2,885,022,540 +$14,409,751 $40.23 177
2024 Q3 69,051,239 $3,268,392,680 +$183,360 $47.33 174
2024 Q2 67,390,465 $2,011,640,213 +$5,551,590 $29.85 153
2024 Q1 67,207,302 $2,701,742,064 +$296,832,171 $40.2 161
2023 Q4 60,455,852 $1,539,280,108 +$89,020,891 $25.46 134
2023 Q3 57,350,132 $797,188,696 -$18,249,775 $13.9 120
2023 Q2 58,230,116 $1,338,678,295 +$29,100,921 $22.99 124
2023 Q1 56,859,649 $1,683,467,091 +$23,131,891 $29.63 123
2022 Q4 56,195,243 $1,402,708,961 +$98,529,765 $24.96 116
2022 Q3 52,859,306 $1,150,805,258 +$29,150,428 $21.77 119
2022 Q2 49,442,050 $973,574,555 +$16,502,218 $19.69 99
2022 Q1 45,688,568 $1,933,296,396 +$62,437,636 $42.32 124
2021 Q4 43,015,870 $2,729,867,438 +$128,644,677 $63.49 123
2021 Q3 34,637,185 $2,035,073,191 +$491,859,746 $58.74 115
2021 Q2 26,479,657 $1,284,263,574 +$188,105,374 $48.5 109
2021 Q1 22,191,421 $862,345,865 +$92,686,286 $38.86 94
2020 Q4 20,299,967 $1,247,002,136 +$53,009,741 $62 74
2020 Q3 16,828,031 $542,529,000 +$542,529,000 $32.31 51